Global Chemotherapy Induced Peripheral Neuropathy Treatment Market – Industry Trends and Forecast to 2029

Análise e tamanho do mercado de tratamento da neuropatia periférica induzida por quimioterapia

De acordo com os dados fornecidos pelos Centros de Controlo e Prevenção de Doenças (CDC), nos EUA, foram testemunhados 1.708.921 novos casos de cancro em 2018 e 599.265 pessoas morreram de cancro. A procura de quimioterapia aumentou em todo o mundo com o aumento da carga de cancro. A neuropatia periférica inclui sintomas que resultam de lesões dos nervos periféricos. A quimioterapia e vários outros medicamentos são utilizados para tratar o cancro que pode causar neuropatia periférica.

A Data Bridge Market Research analisa uma taxa de crescimento no mercado global de tratamento da neuropatia periférica induzida por quimioterapia no período de previsão 2022-2029. O CAGR esperado do mercado global de tratamento da neuropatia periférica induzida por quimioterapia tende a rondar os 5,66% no período de previsão mencionado. O mercado foi avaliado em 967,73 milhões de dólares em 2021 e cresceria até 1.503,28 milhões de dólares até 2029. Além dos insights de mercado, como o valor de mercado, taxa de crescimento, segmentos de mercado, cobertura geográfica, participantes no mercado e cenário de mercado, o O relatório de mercado com curadoria da equipa de pesquisa de mercado da Data Bridge inclui também uma análise especializada aprofundada, epidemiologia dos doentes, análise de pipeline, análise de preços e estrutura regulamentar.

Âmbito e segmentação do mercado de tratamento da neuropatia periférica induzida por quimioterapia

Definição de mercado

A neuropatia periférica induzida pela quimioterapia é um tipo grave de condição clínica induzida por uma série de medicamentos quimioterápicos ou citotóxicos, como a platina, os alcalóides da vinca, os taxanos, a eribulina, as epotilonas e o bortezomib. Todas estas drogas causam problemas patológicos alterados nos neurónios. Os problemas patológicos levam à degeneração dos nervos periféricos sensitivos e motores que podem provocar nos doentes perturbações sensitivas, problemas de equilíbrio ou fraqueza.

Dinâmica global do mercado de tratamento da neuropatia periférica induzida por quimioterapia

Motoristas

• Aumento de tratamentos avançados

Os crescentes métodos de tratamento avançados estão a impulsionar o crescimento do mercado. Os tratamentos avançados contra o cancro melhoram a sobrevivência dos doentes e aumentam o número de doentes que necessitam de quimioterapia ambulatória de longa duração. Mais exposição à quimioterapia pode resultar num número crescente destes casos doentes, impulsionando assim o crescimento do mercado da neuropatia periférica induzida pela quimioterapia. Assim, atua como um grande impulsionador do crescimento do mercado.

• Aumento da prevalência do cancro

Foi testemunhado que, por cada 100.000 pessoas, foram observados 436 novos casos de cancro e 149 pessoas morreram de cancro. De acordo com os dados publicados pela Agência Internacional de Investigação sobre o Cancro (IARC), 22.81.658 novos casos de cancro foram testemunhados em 2020 nos EUA, onde o cancro da mama foi predominante, representando 11,1% de todos os casos notificados . Isto impulsiona o crescimento do mercado.

Oportunidades

• Aumento do tabagismo e alterações no estilo de vida

O tabagismo é uma das principais causas de doenças e mortes evitáveis ​​nos EUA. Além disso, as mudanças no estilo de vida alcançadas pela população atual, como o estilo de vida pouco saudável, a alimentação inadequada, o stress e muitos destes fatores, contribuem para o desenvolvimento de oportunidades de mercado.

• Iniciativas crescentes por parte dos participantes do mercado

As iniciativas crescentes de diversos players do mercado estão a criar muitas oportunidades para o crescimento do mercado. Por exemplo, em março de 2020, a Regenacy Pharmaceuticals anunciou o fecho de um financiamento Série A de 30 milhões de dólares. Esta iniciativa foi co-liderada pela Cobro Ventures e pela Taiwania Capital Management Corporation, com a participação ativa da Yonjin Capital, 3E Bioventures Capital, VIVA Biotech Holdings e TA YA VENTURE HOLDINGS LIMITED, e outros vários investidores privados não divulgados.  

Restrições/Desafios

• Falta de profissionais qualificados

The lack of qualified personnel who are unable to perform these treatments could limit the growth of the global chemotherapy induced peripheral neuropathy treatment market over a forecast period.

• High Cost

The huge expenditure required for the treatment processes hamper the market growth. High costs are associatred with chemotherapy regimens, which somewhat hamper the market's growth.

This global chemotherapy induced peripheral neuropathy treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global chemotherapy induced peripheral neuropathy treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Chemotherapy Induced Peripheral Neuropathy Treatment Market

 COVID-19 has left a major global public health crisis that has impacted practically every market sector. Its long-term consequences are expected to boost the industry growth during the forecast period.

The load on healthcare facilities and professionals was increasing with the rapid surge in patient numbers. Many hospitals have decided to cancel or postpone procedures. The pandemic had a mixed influence on the global chemotherapy induced peripheral neuropathy treatment market. The pandemic has put a strain on the treatment procedures in general. As a result of the lockdown and travel restrictions, the number of hospitals has decreased and countless drives have been cancelled around the world.

Recent Developments:

• In December 2020, for the development of ricolinostat, Regenacy announced a joint venture with 3E Bioventures in China, which will be further followed by a U.S.-based phase 2 study in patients with painful diabetic peripheral neuropathy and other peripheral neuropathies. This collaboration will evaluate the efficacy and safety of ricolinostat in patients having chemotherapy-induced peripheral neuropathy in China.

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Scope

The global chemotherapy induced peripheral neuropathy treatment market is segmented on the basis of drug class, drug type, treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Nerve Protective Therapy
• Anti-Inflammatory Therapy
• Neurotransmitter Based Therapy
• Antioxidant
• Others

Treatment

• Medication
• Therapy
• Others

Drug Type

• Branded
• Generic

End-User

• Hospitals
• Research Institutes
• Specialty Clinics

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Chemotherapy Induced Peripheral Neuropathy Treatment Market Regional Analysis/Insights

The global chemotherapy induced peripheral neuropathy treatment market is analyzed and market size insights and trends are provided by drug class, drug type, treatment, distribution channel and end-user as referenced above.

The major countries covered in the global chemotherapy induced peripheral neuropathy treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market in the forecast period due to the presence of high healthcare expenditure and favourable reimbursement policies for the treatment.

Asia-Pacific is expected to have the largest market share over coming years for the chemotherapy-induced peripheral neuropathy treatment market due to the constant rise in cancer incidence with increased demand for cost-efficient therapeutics.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share Analysis

The global chemotherapy induced peripheral neuropathy treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global chemotherapy induced peripheral neuropathy treatment market.

Key players operating in the global chemotherapy induced peripheral neuropathy treatment market include:

• Alexion Pharmaceuticals, Inc. (U.S.)
• Sanofi (France)
• Takeda Pharmaceutical Company Limited (Japan)
• Vertex Pharmaceuticals Incorporated (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Abbott (U.S.)
• Amgen Inc. (U.S.)
• Jazz Pharmaceuticals, Inc. (U.K.)
• Asahi Kasei Pharma Corporation (Japan)
• Solasia Pharma K.K. (Japan)
• Immunepharma.com. (U.S.)

SKU-59261